cystic
fibrosi
cf
common
genet
diseas
affect
caucasian
popul
unit
state
believ
transmit
autosom
recess
disord
incid
live
birth
countri
affect
male
femal
equal
found
vari
incid
racial
ethnic
group
diseas
character
malabsorpt
chronic
obstruct
pulmonari
diseas
high
salt
content
sweat
diseas
affect
endocrin
gland
secret
throughout
bodi
although
impact
multipl
bodi
system
gastrointestin
endocrin
neurolog
import
life
threaten
effect
involv
lung
thu
cf
major
caus
chronic
pulmonari
diseas
children
major
caus
morbid
mortal
young
adult
patient
cf
lifetim
bacteri
bronchiti
despit
aggress
multipl
antibiot
therapi
typic
children
present
recurr
lower
respiratori
tract
infect
characterist
sputum
bacteriolog
although
patient
carri
multipl
strain
normal
oropharyng
flora
secret
varieti
specif
organ
associ
lower
respiratori
tract
infect
patient
cf
prior
use
antibiot
staphylococcu
aureu
organ
frequent
isol
sputum
patient
cf
predomin
chang
dramat
pseudomona
aeruginosa
past
decad
undoubtedli
antibiot
use
aureu
continu
frequent
isol
patient
cf
infant
cf
usual
acquir
aureu
part
respiratori
flora
within
first
year
birth
colon
appear
carri
organ
life
longterm
colon
phage
type
typic
phage
type
associ
cf
uniqu
similar
seen
commun
cf
patient
carri
aureu
greater
number
infect
requir
hospit
often
colon
organ
isol
aureu
respiratori
secret
sputum
alway
report
clinic
microbiolog
laboratori
regardless
number
coloni
isol
gener
aureu
isol
cf
patient
resist
antibiot
seen
commun
antibiot
use
respons
decreas
preval
aureu
cultur
sputum
patient
cf
also
respons
increas
preval
p
aeruginosa
p
aeruginosa
associ
cf
use
antimicrobi
therapi
patient
cf
carri
p
aeruginosa
lung
coloni
morpholog
mani
p
aeruginosa
strain
isol
cf
patient
uniqu
half
strain
mucoid
coloni
appear
slime
coat
factor
thought
contribut
persist
pseudomona
lung
cf
patient
believ
nonmucoid
strain
p
aeruginosa
initi
colon
respiratori
tract
cf
patient
later
transit
mucoid
strain
associ
chronic
infect
poorer
prognosi
like
aureu
p
aeruginosa
colon
lost
patient
cf
preval
p
aeruginosa
sputum
cultur
patient
increas
age
earli
cf
investig
classifi
p
aeruginosa
strain
rough
classic
smooth
mucoid
present
terminolog
mucoid
nonmucoid
use
simplifi
report
patient
cf
usual
harbor
mixtur
mucoid
nonmucoid
strain
colon
andor
infect
two
p
aeruginosa
strain
common
cf
patient
strain
isol
patient
shown
antigen
type
mucoid
p
aeruginosa
strain
isol
respiratori
secret
patient
cf
appear
specif
diseas
consid
mani
pathognomon
mucoid
p
aeruginosa
strain
usual
nonpig
produc
exopolysaccharid
appear
polym
guluron
mannuron
acid
product
substanc
origin
thought
relat
presenc
bacteriophag
appear
product
mucoid
materi
chromosom
determin
vitro
slime
product
mucoid
strain
unstabl
usual
lost
repeat
subcultur
vivo
organ
appear
retain
abil
produc
exopolysaccharid
indefinit
mucoid
strain
escherichia
coli
klebsiella
ozaena
also
isol
cf
patient
mucoid
substanc
purifi
e
coli
isol
biochem
antigen
differ
p
aeruginosa
polym
lung
patient
cf
appear
offer
environ
conduc
product
mucoid
coat
number
gramneg
rod
gener
enterobacteriacea
rare
constitut
predomin
gramneg
respiratori
flora
seen
cf
patient
mucoid
nonmucoid
variant
p
aeruginosa
patient
appear
serotyp
pyocin
type
phage
type
share
biochem
properti
use
vitro
suscept
test
method
mucoid
strain
p
aeruginosa
found
suscept
antibiot
nonmucoid
strain
laboratori
observ
differ
frequent
discrep
occur
vitro
suscept
test
result
p
aeruginosa
isol
clinic
respons
antibiot
therapi
cf
patient
usual
colon
multipl
strain
p
aeruginosa
unlik
strain
select
vitro
test
laboratori
repres
strain
present
patient
lung
laboratori
attempt
minim
problem
select
separ
test
wide
crosssect
mucoid
nonmucoid
p
aeruginosa
strain
vitro
suscept
number
investig
attempt
type
p
aeruginosa
isol
cf
patient
use
either
homma
intern
serotyp
system
investig
indic
preval
specif
serotyp
p
aeruginosa
cf
patient
other
report
wide
heterogen
serotyp
seen
data
conflict
confus
appear
ideal
system
time
type
p
aeruginosa
strain
cf
patient
mani
cf
center
pseudomona
cepacia
recent
emerg
caus
sever
frequent
fatal
pneumonia
number
cf
patient
exhibit
rapid
clinic
deterior
death
follow
p
cepacia
colon
organ
great
concern
work
cf
patient
p
cepacia
colon
patient
cf
clearli
shown
associ
increas
morbid
earlier
death
like
p
aeruginosa
p
cepacia
appear
abl
colon
lung
cf
patient
long
period
time
without
sever
effect
sign
infect
present
estim
mani
cf
children
less
year
age
greater
year
age
p
cepacia
sputum
prior
appear
cf
popul
p
cepacia
implic
nosocomi
outbreak
note
caus
respiratori
tract
infect
periton
occasion
bacteremia
p
cepacia
colon
andor
infect
patient
cf
howev
appear
result
hospit
outbreak
number
risk
factor
includ
patient
age
sever
cf
anteced
use
aminoglycosid
recent
hospit
sibl
colon
nebul
disinfect
contamin
associ
acquisit
p
cepacia
still
unclear
patient
cf
becom
colon
p
cepacia
signific
isol
patient
cf
laboratori
deal
cf
patient
adopt
routin
use
p
cepacia
select
media
cultur
respiratori
specimen
number
excel
select
media
avail
center
note
increas
isol
rate
awar
p
cepacia
select
medium
employ
organ
tend
grow
slowli
may
take
long
h
appear
select
media
strain
p
cepacia
abl
produc
phenazin
pigment
like
p
aeruginosa
unfamiliar
organ
use
select
differenti
medium
make
initi
recognit
organ
much
easier
p
cepacia
strain
character
bacteriocin
product
biotyp
serotyp
system
two
biotyp
system
separ
strain
either
four
eight
biovar
sever
serotyp
scheme
p
cepacia
propos
one
classif
base
seven
somat
five
flagellar
h
antigen
none
serotyp
system
appear
popular
use
time
consid
preliminari
p
cepacia
tend
develop
resist
antibiot
patient
colon
organ
seem
sever
lung
diseas
poorer
prognosi
patient
colon
p
aeruginosa
aureu
p
cepacia
normal
resist
polymyxin
aminoglycosid
first
second
gener
cephalosporin
antipseudomon
penicillin
carbenicillin
ticarciuin
resist
chloramphenicol
trimethoprimsulfamethoxazol
appear
vari
isol
imipenem
aztreonam
ciprofloxacin
number
third
gener
cephalosporin
demonstr
vitro
activ
p
cepacia
p
aeruginosa
complet
erad
p
cepacia
appear
imposs
even
strain
suscept
specif
antibiot
laboratorian
awar
organ
multipl
resist
usual
profil
antibiot
use
vitro
antibiot
suscept
test
may
adequ
deal
p
cepacia
haemophilu
spp
frequent
isol
respiratori
tract
patient
cf
studi
haemophilu
spp
isolatedrom
patient
mycobacterium
tuberculosi
rare
seen
patient
cf
cf
lung
appear
resist
organ
mani
believ
due
hypoxemia
present
within
lung
one
studi
involv
patient
two
case
activ
pulmonari
tuberculosi
document
although
fungi
includ
candida
spp
infrequ
seen
patient
cf
incid
allerg
bronchopulmonari
aspergillosi
abpa
report
high
origin
thought
affect
older
adolesc
young
adult
patient
abpa
seen
younger
cf
patient
well
patient
abpa
present
typic
symptom
asthma
usual
cough
wheez
may
also
fever
malais
pleurit
chest
pain
unfortun
typic
cours
patient
cf
experienc
pulmonari
exacerb
reason
diagnosi
abpa
patient
cf
difficult
cf
patient
experienc
exacerb
improv
appropri
antibiot
treatment
continu
pulmonari
infdtrat
wheez
increas
cough
eosinophilia
diagnosi
abpa
consid
diagnost
featur
abpa
includ
elev
serum
ige
averag
episod
peak
iuml
precipit
igg
antibodi
aspergillu
antigen
serum
eosinophilia
greater
immedi
type
hypersensit
aspergillu
antigen
acut
pulmonari
infiltr
atelectasi
pathogenesi
abpa
complet
understood
believ
aspergillu
spore
deposit
thick
respiratori
secret
patient
spore
grow
host
respons
larg
allerg
immunolog
reaction
reaction
involv
complement
activ
pulmonari
damag
eosinophil
pneumonia
often
seen
varieti
aspergillu
spp
report
caus
abpa
fumigatu
common
cf
patient
commonli
increas
frequenc
posit
skin
test
sputum
cultur
precipit
antibodi
aspergillu
gener
patient
cf
higher
colon
rate
aspergillu
spp
noncf
popul
thu
mani
criteria
use
diagnos
abpa
also
strongli
associ
cf
absenc
abpa
isol
aspergillu
spp
cultur
alon
suffici
criterion
acut
chang
chest
radiograph
inclin
microbiolog
newslett
creas
serum
lge
level
consid
reliabl
indic
abpa
isol
aspergillu
spp
patient
cf
report
role
virus
mycoplasma
chlamydia
lower
respiratori
pathogen
children
adult
cf
extens
evalu
one
studi
children
cf
sever
exacerb
shown
associ
viral
infect
primarili
respiratori
syncyti
viru
rsv
influenza
viru
influenza
viru
infect
thought
signific
caus
death
patient
cf
influenza
vaccin
routin
given
cf
patient
second
studi
correl
incid
acut
respiratori
exacerb
possibl
etiolog
agent
show
episod
associ
bacteria
nonbacteri
respiratori
agent
nonbacteri
episod
caus
rsv
parainfluenza
viru
influenza
viru
adenoviru
mycoplasma
chlamydia
unfortun
serolog
evid
use
implic
nonbacteri
agent
neither
studi
examin
role
rhinovirus
coronavirus
microbiolog
lower
respiratori
tract
patient
cf
extrem
complex
mani
differ
organ
contribut
diseas
pathogenesi
patient
cf
clearli
high
risk
develop
sever
lifethreaten
respiratori
infect
varieti
pathogen
throughout
live
mechan
pathogenesi
bacteri
infect
part
unknown
aureu
acquir
earli
life
follow
p
aeruginosa
p
aeruginosa
persist
domin
pathogen
caus
pulmonari
diseas
cf
patient
colon
p
aeruginosa
establish
erad
appear
imposs
consequ
patient
receiv
antistaphylococc
antipseudomon
therapi
continu
h
influenza
infect
also
common
rsv
infect
patient
advanc
pulmonari
diseas
uncommon
find
varieti
p
aeruginosa
strain
aureu
aspergillu
spp
sputum
cultur
alarm
new
pathogen
p
cepacia
full
impact
patient
cf
yet
appreci
michael
grave
ms
clinic
microbiologist
left
hospit
laboratori
work
compani
manufactur
product
field
often
ask
friend
like
go
industri
question
rang
want
leav
clinic
laboratori
go
commerci
burnt
like
realli
like
answer
question
necessarili
straightforward
simpl
probabl
vari
among
individu
work
differ
compani
us
clinic
microbiolog
year
time
left
senior
laboratori
supervisor
univers
medic
center
staff
approxim
work
progress
clinic
laboratori
challeng
stimul
also
often
frustrat
exhaust
manag
clinic
laboratori
easi
task
gratifi
abl
conduct
smallscal
research
evalu
project
teach
microbiolog
variou
type
student
attend
continu
educ
seminar
nation
meet
leav
laboratori
felt
need
chang
new
challeng
new
experi
new
way
profession
impact
clinic
microbiolog
felt
without
doctor
degre
could
advanc
much
clinic
laboratori
microbiolog
remain
profess
choic
independ
sought
posit
diagnost
product
compani
present
individu
posit
within
compani
quit
differ
one
market
one
product
develop
path
given
us
opportun
growth
profession
develop
attempt
convey
impress
work
compani
manufactur
product
clinic
microbiolog
laboratori
gener
differ
hospit
industri
environ
simplist
term
compani
goal
make
money
hospit
goal
cure
patient
although
hospit
becom
increasingli
businesslik
basic
goal
affect
work
environmentcultur
exampl
institut
certain
test
hospit
factor
consid
base
clinic
relev
costeffect
within
compani
factor
consid
develop
sell
given
product
includ
market
size
develop
cost
product
cost
product
competit
clinic
laboratori
amount
mix
work
dictat
workload
function
physician
propens
order
test
well
patient
popul
hospit
particular
time
industri
work
dictat
market
composit
custom
individu
custom
need
desir
compani
major
concern
econom
need
make
univers
product
need
individu
laboratori
must
balanc
need
microbiolog
laboratori
clinic
laboratori
crise
tend
daytoday
patient
unusu
test
result
instrument
failur
industri
crise
tend
lengthi
chang
raw
materi
could
affect
product
perform
track
exact
compon
caus
troubl
find
altern
compon
make
formul
chang
take
month
great
extent
hospit
environ
technic
inform
one
tri
commun
understood
physician
nurs
alli
healthcar
worker
industri
set
one
commun
divers
group
peopl
disciplin
exampl
compani
probabl
peopl
spend
work
day
make
support
microbiolog
product
realli
know
escherichia
coli
hand
shuffl
paper
attend
meet
seem
univers
function
institut
success
busi
provid
use
costeffect
highqual
product
custom
want
laboratori
product
time
accur
test
report
clinic
use
inform
physician
compani
goal
make
product
enabl
laboratori
gener
result
easier
faster
accur
laboratori
immedi
